BiotechPark with Innovation- and Incubationscenter
Berlin-Buch, with its long tradition of excellent biomedical basic and clinical research as well as clinical expertise, is an ideal environment for life science companies. The campus atmosphere is conducive to scientific exchange, technology transfer and collaborative projects.
With an area of approximately 31,000 m², the BiotechPark Berlin-Buch is one of the largest biotech parks in Germany. Here entrepreneurs and companies find affordable, industry-specific laboratory and office space with state-of-the-art facilities. Start-ups can grow and thrive in the Innovation and Incubation Center, building areas on the Campus allow for future development. The managing company, Campus Berlin-Buch GmbH, supports the companies in all matters and provides comprehensive service.
Currently, approximately 61 companies are located on campus and employ around 800 people. Forty-four of these companies are in the biotech sector, several others offer services for the life science industry. Since 1998 the number of employees of the biotech companies has more than doubled.
The business fields of the companies range from medical technology products, molecular biological diagnostics and treatments, preclinical pharmacological and pharmacogenomic tests, RNA technologies, the search for pharma-relevant target molecules, production and testing of drugs and the analysis and synthesis of biomolecules.
From 2023 the new BerlinBioCube start-up center in BiotechPark Berlin-Buch will offer an additional 8,000 square meters of laboratory and office space and attractive services for start-ups in the fields of biotechnology and medical technology as well as adjacent areas.
„Made in Buch“ stands for high quality and innovation in the life sciences. Selected products can be found here.
Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in Berlin
2021-04-14 / Eckert & Ziegler is proud to announce that it is expanding its production site in Berlin, Germany, with a new production facility for the contract manufacturing of radiopharmaceuticals.more ...
Eckert & Ziegler Receives Technetium Generator Licenses for Brazil
The Brazilian regulator ANVISA has provided Eckert & Ziegler Brasil Comercial Ltda., a fully owned subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), with a li...more ...
Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit Increase in 2020. Positive Outlook for 2021.
Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 176.1 million (previous year EUR 178.5 million) and a net profit of EUR 22.9 million (previous year EUR 22.0 million) in the 2020 ...more ...
Epigenetik und die große Frage: Beeinflusst die Umwelt unser Erbgut?
Die Epigenetik bietet konzeptionell neue Ansätze für das Verständnis genetischer Regulation von Entwicklungs- und Erkrankungs-Prozessen.more ...
GMP Biotech Summer School
Good Manufacturing Practice (GMP) Basic Course Biotechnology (English)more ...
Pharmacokinetics - Essentials for Project Managers in Biotech Companies
Basics in understanding pharmacokinetics in clinicial development - for non-physiciansmore ...